Eli Lilly recently announced the retirement of Mike Mason, the executive vice president and president of Lilly Diabetes & Obesity. After dedicating 34 years to the Indianapolis drugmaker, Mason will be leaving at the end of the year.
During his tenure, Mason played a pivotal role in the development and successful launch of Mounjaro, a renowned diabetes drug. Notably, this medication has garnered recognition for its off-label use in weight loss, pending approval from the U.S. Food and Drug Administration for obesity treatment. The popularity of Mounjaro has also contributed to Eli Lilly's impressive market capitalization surpassing $500 billion.
Effective from January 1, Patrik Jonsson, the current executive vice president and president of Lilly USA, will take on the additional responsibility of being the president of Lilly Diabetes & Obesity. At the same time, Daniel Skovronsky, the chief scientific officer and president of Lilly Research Laboratories, will assume the role of president of Lilly Immunology, previously held by Jonsson.
We thank Mike Mason for his exceptional commitment and contributions and wish him all the best in his retirement.
